Guangdong Biolight Meditech Co Ltd Working Capital to Net Assets Ratio
Guangdong Biolight Meditech Co Ltd working capital to net assets ratio. Guangdong Biolight Meditech Co Ltd (300246) has a Working Capital to Net Assets ratio of 32.0% as of June 2026. Working capital of CN¥376.42 Million (current assets of CN¥1.23 Billion minus current liabilities of CN¥855.31 Million) is measured against net assets of CN¥1.18 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Guangdong Biolight Meditech Co Ltd (2008–2025)
Working capital to net assets ratio of Guangdong Biolight Meditech Co Ltd from 2008 to 2025. This chart shows how Guangdong Biolight Meditech Co Ltd's Working Capital to Net Assets ratio has evolved across 18 annual periods from 2008 to 2025. As of June 2026, the ratio stands at 32.0%, reflecting working capital of CN¥376.42 Million against net assets of CN¥1.18 Billion CNY. Explore 300246 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Guangdong Biolight Meditech Co Ltd Working Capital to Net Assets Ratio by Year (2008–2025)
Guangdong Biolight Meditech Co Ltd working capital to net assets ratio by year from 2008 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Guangdong Biolight Meditech Co Ltd from 2008 to 2025, covering 18 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see total assets of Guangdong Biolight Meditech Co Ltd.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 39.0% | CN¥473.10 Million | CN¥1.21 Billion | CN¥1.28 Billion | CN¥802.54 Million | ▼ -11.9 pp |
| 2024 | 51.0% | CN¥657.87 Million | CN¥1.29 Billion | CN¥1.33 Billion | CN¥675.82 Million | ▲ +7.7 pp |
| 2023 | 43.2% | CN¥600.70 Million | CN¥1.39 Billion | CN¥1.37 Billion | CN¥770.70 Million | ▼ -5.5 pp |
| 2022 | 48.8% | CN¥732.50 Million | CN¥1.50 Billion | CN¥1.34 Billion | CN¥603.39 Million | ▲ +15.2 pp |
| 2021 | 33.5% | CN¥332.56 Million | CN¥992.38 Million | CN¥829.76 Million | CN¥497.20 Million | ▼ -12.2 pp |
| 2020 | 45.7% | CN¥471.81 Million | CN¥1.03 Billion | CN¥866.46 Million | CN¥394.65 Million | ▲ +5.9 pp |
| 2019 | 39.8% | CN¥233.31 Million | CN¥585.84 Million | CN¥494.46 Million | CN¥261.15 Million | ▼ -4.3 pp |
| 2018 | 44.1% | CN¥274.56 Million | CN¥622.19 Million | CN¥487.31 Million | CN¥212.76 Million | ▲ +2.8 pp |
| 2017 | 41.3% | CN¥228.87 Million | CN¥554.08 Million | CN¥458.57 Million | CN¥229.71 Million | ▼ -6.5 pp |
| 2016 | 47.8% | CN¥241.02 Million | CN¥504.27 Million | CN¥410.37 Million | CN¥169.35 Million | ▼ -14.2 pp |
| 2015 | 62.0% | CN¥285.79 Million | CN¥460.87 Million | CN¥395.14 Million | CN¥109.35 Million | ▲ +1.5 pp |
| 2014 | 60.5% | CN¥258.82 Million | CN¥427.94 Million | CN¥338.19 Million | CN¥79.37 Million | ▼ -10.6 pp |
| 2013 | 71.1% | CN¥279.94 Million | CN¥393.88 Million | CN¥346.65 Million | CN¥66.71 Million | ▼ -15.1 pp |
| 2012 | 86.2% | CN¥325.79 Million | CN¥377.93 Million | CN¥375.04 Million | CN¥49.25 Million | ▼ -8.2 pp |
| 2011 | 94.4% | CN¥334.54 Million | CN¥354.32 Million | CN¥368.75 Million | CN¥34.21 Million | ▲ +13.7 pp |
| 2010 | 80.8% | CN¥72.63 Million | CN¥89.93 Million | CN¥108.47 Million | CN¥35.84 Million | ▼ -1.0 pp |
| 2009 | 81.8% | CN¥54.76 Million | CN¥66.94 Million | CN¥85.71 Million | CN¥30.94 Million | ▲ +5.6 pp |
| 2008 | 76.2% | CN¥35.47 Million | CN¥46.53 Million | CN¥61.84 Million | CN¥26.37 Million | — |